newsfilter
← Latest News
GlobeNewswire·

IMAC Holdings, Inc. Announces Completion of Third Cohort of its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the Treatment of Bradykinesia Due to Parkinson's Disease

BRENTWOOD, Tenn., Sept. 09, 2022 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (NASDAQ:BACK) ("IMAC" or "the Company"), today announces it has completed the third cohort of its Phase 1 clinical trial for its investigational compound utilizing umbilical cord-